Pre-Clinical Imaging (In vivo) Market - By Systems and Reagents [Micro-PET, Optical Imaging, Micro-MRI, Micro-SPECT, Micro-Ultrasound, Micro-CT & Multimodality/Hybrid Imaging Modalities] - Competitive Analysis & Global Forecasts to 2017

NEW YORK, Dec. 27, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pre-Clinical Imaging (In vivo) Market – By Systems and Reagents [Micro-PET, Optical Imaging, Micro-MRI, Micro-SPECT, Micro-Ultrasound, Micro-CT & Multimodality/Hybrid Imaging Modalities] - Competitive Analysis & Global Forecasts to 2017

http://www.reportlinker.com/p01054129/Pre-Clinical-Imaging-In-vivo-Market-–-By-Systems-and-Reagents-[Micro-PET-Optical-Imaging-Micro-MRI-Micro-SPECT-Micro-Ultrasound-Micro-CT--Multimodality/Hybrid-Imaging-Modalities]---Competitive-Analysis--Global-Forecasts-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

Pre-clinical imaging technologies are excellent tools for assessment of anatomical, physiological and functional parameters at molecular and cellular levels in the live animal models. It plays a significant role in the assessment of specific drug candidate or treatment regime, in phenotyping and understanding the pathophysiology of various diseases.

The global pre-clinical imaging (in vivo) market has witnessed challenging and dynamic market conditions in terms of government funding/grants and technological advancements in the last five years. The overall pre-clinical imaging (in vivo) market is valued at $790 million in 2012, and is estimated to grow at an annual growth rate of 14.5% over the next five years. Market displays growing preference for new technologies such as hybrid systems – PET + MRI, SPECT + MRI and PET + SPECT + CT, for the continuum of advantages offered by them over traditional standalone techniques as they enable to overcome limitations of each technology. Pre-clinical imaging (in vivo) industry has witnessed myriad technological advancements over the last two decades and it is expected that this trend will continue in future to solve the present challenges and fill the unmet needs of the market.

Factors such as increasing pre-clinical research studies, technological advancements, rising government support in developing markets, growing use of functional imaging, and increasing number of pharma companies and research institutions, are spurring the growth of pre-clinical imaging market. However, high cost of imaging systems and technological limitations are restraining the market growth. Market is facing some major challenges such as industry consolidation, slow adoption rate of pre-clinical imaging technologies by tier I and tier II pharma/biotech companies and lack of sufficient accessibility of radiotracers for nuclear imaging.

In 2012, North America is the biggest market, about 38.2% share of the global pre-clinical imaging (in vivo) systems and reagents market, followed by Europe. However, the Asian and Latin American countries represent the fastest growing markets due to increasing government support for research, growing number of research institution and CRO's, and rising industry-academia partnerships for pre-clinical research. Moreover, economic slowdown, pricing pressures and high competition in mature countries will compel the companies to focus on the Asian market.

Market has opportunity for imaging systems which will be cost effective with applications in multiple fields. In addition, unique combinations of imaging modalities such as MRI and optical imaging, which will address the challenges associated with the currently marketed imaging combinations are expected to have better future prospects for growth.

Pre-clinical imaging market is highly competitive, with each player vying to make a mark and gain a large market share. Rapid industry consolidation is a burning issue in the market currently, which not only affects the small market players but also enforces big players to redefine their marketing strategies.

The key players in this market are Siemens AG (Germany), PerkinElmer, Inc. (U.S.), Bruker Corporation (U.S.), Bioscan, Inc. (U.S.), Mediso Medical Imaging Systems (Hungary), Gamma Medica (U.S.), FUJIFILM Holdings Corporation (Japan), Aspect Imaging (Israel), Miltenyi Biotec GmbH (Germany), Life Technologies Corporation (U.S.), Scanco Medical (Switzerland), and Targeson, Inc. (U.S.).

Table of contents

1 Introduction 19

1.1 Key Take-Aways 19

1.2 Report Description 19

1.3 MARKETS COVERED 21

1.4 STAKEHOLDERS 22

1.5 RESEARCH METHODOLOGY 22

1.5.1 Market size 22

1.5.2 Market share 24

1.5.3 Key Data Points from secondary sources 24

1.5.4 Key Data Points from Primary sources 24

1.5.5 assumptions 25

2 Executive summary 26

3 Market Overview 32

3.1 introduction 33

3.2 Market segmentation 36

3.2.1 pre-clinical imaging (in vivo) market,

by technology 36

3.2.2 pre-clinical imaging (in vivo) market,

by reagents 39

3.3 Market dynamics 40

3.3.1 drivers 41

3.3.1.1 Technological Advancements 41

3.3.1.2 Growing Adoption Rate for Pre-clinical Imaging 42

3.3.1.3 Rising Application of Functional Imaging 42

3.3.1.4 Increasing Number of Pharma Companies and Research Institutions 43

3.3.2 Restraints 43

3.3.2.1 High Device Cost 43

3.3.2.2 Technological Limitations 44

3.3.2.3 High Cost and Data Requirements for Bringing New Technology 44

3.3.3 Opportunities 45

3.3.3.1 Next Unique Combinations in MRI 45

3.3.3.2 High Resolution & Sensitivity of Imaging Devices with Usage in Multiple Applications 45

3.3.3.3 Emerging Markets 46

3.3.4 Challenges 46

3.3.4.1 Sustainability of Players in Highly Competitive Market 46

3.3.4.2 Availability of Radiopharmaceuticals 47

3.4 Market share analysis 48

3.4.1 by technology 48

3.4.2 BY market players 48

3.4.3 By geography 51

4 Global pre-clinical imaging (in vivo) systems Market, by technology 52

4.1 Introduction 53

4.2 standalone technology for pre-clinical imaging (in vivo) 55

4.2.1 Nuclear imaging 58

4.2.1.1 Micro-SPECT 60

4.2.1.2 Micro-PET 61

4.2.2 Optical imaging 63

4.2.2.1 Fluorescence 66

4.2.2.2 Bioluminescence 67

4.2.2.3 Near Infrared Fluorescence 68

4.2.3 Micro-MRI 70

4.2.4 Micro-CT 72

4.2.5 micro-Ultrasound 74

4.3 Multimodal imaging for pre-clinical imaging

(in vivo) 76

4.3.1 Multimodal nuclear imaging devices 77

4.3.1.1 SPECT + CT 78

4.3.1.2 SPECT + MR 79

4.3.1.3 PET + CT 80

4.3.1.4 PET + MR 81

4.3.1.5 SPECT + PET + CT 82

4.3.2 Multimodal Optical imaging devices 83

4.3.2.1 Optical+ X-ray + Radioisotopic 83

5 Global pre-clinical IMAGING (IN VIVO) market,

BY REAGENTS 84

5.1 Introduction 85

5.2 Nuclear imaging for pre-clinical imaging

(in vivo) 87

5.2.1 PET Tracers 89

5.2.1.1 Fluorine-18 based 93

5.2.1.2 Carbon-11 based 94

5.2.1.3 Copper-64 based 95

5.2.1.4 Others 96

5.2.2 SPECT probes 97

5.2.2.1 Technetium-99m based 98

5.2.2.2 Iodine-131 based 100

5.2.2.3 Gallium-67 based 101

5.2.2.4 Thallium-201 based 102

5.2.2.5 Others 103

5.3 Optical imaging for pre-clinical imaging (in vivo) 104

5.3.1 Bioluminescence 105

5.3.1.1 Luciferins 107

5.3.1.2 Proluciferins 109

5.3.1.3 Coelenterazine 110

5.3.1.4 Others 111

5.3.2 FLUORESCENCE 112

5.3.2.1 Green Fluorescent Proteins 115

5.3.2.2 Red Fluorescent Proteins 116

5.3.2.3 Infrared Dyes 117

5.3.2.4 Others (Natural fluorescence Molecules such as Collagen and Elastin) 118

5.4 MRI contrast reagents for pre-clinical imaging (in vivo) 120

5.4.1 Gadolinium based 121

5.4.2 Iron based 122

5.5 CT contrast reagents for pre-clinical imaging

(in vivo) 124

5.5.1 Iodine based 126

5.5.2 Barium based 127

5.5.3 Gastrografin based 128

5.6 Ultrasound contrast reagents for pre-clinical imaging (in vivo) 129

5.6.1 Gadolinium Oxide Albumin Microspheres - GOAM 130

6 Geographic Analysis 132

6.1 Introduction 133

6.2 NORTH AMERICA 134

6.3 Europe 140

6.4 Asia-pacific 145

6.5 Rest of the world (RoW) 152

7 COMPETITIVE LANDSCAPE 157

7.1 Introduction 157

8 Company Profiles 179

8.1 Agilent technologies, inc. 179

8.1.1 Overview 179

8.1.2 Financials 179

8.1.3 Products & services 182

8.1.4 Strategy 183

8.1.5 Developments 183

8.2 aspect imaging 184

8.2.1 Overview 184

8.2.2 Financials 184

8.2.3 Products & services 184

8.2.4 Strategy 185

8.2.5 Developments 186

8.3 bioscan, inc. 188

8.3.1 Overview 188

8.3.2 Financials 188

8.3.3 Products & services 188

8.3.4 Strategy 190

8.3.5 Developments 191

8.4 bruker corporation 193

8.4.1 Overview 193

8.4.2 Financials 193

8.4.3 Products & services 198

8.4.4 Strategy 200

8.4.5 Developments 202

8.5 FUJIFILM HOLDINGS CORPORATION 204

8.5.1 Overview 204

8.5.2 Financials 205

8.5.3 Products & services 207

8.5.4 Strategy 208

8.5.5 Developments 209

8.6 Gamma Medica-Ideas, Inc. 210

8.6.1 Overview 210

8.6.2 Financials 210

8.6.3 Products & Services 211

8.6.4 Strategy 211

8.7 genovis ab 212

8.7.1 Overview 212

8.7.2 Financials 212

8.7.3 Products & Services 214

8.7.4 Strategy 215

8.7.5 Developments 215

8.8 li-cor biosciences 217

8.8.1 Overview 217

8.8.2 Financials 217

8.8.3 Products & services 218

8.8.4 Strategy 219

8.8.5 Developments 220

8.9 life technologies corporation 224

8.9.1 Overview 224

8.9.2 Financials 224

8.9.3 Products & services 227

8.9.4 Strategy 228

8.9.5 Developments 229

8.10 Mediso Medical Imaging Systems 230

8.10.1 Overview 230

8.10.2 Financials 230

8.10.3 Products & SERVICES 230

8.10.4 Strategy 231

8.10.5 Developments 232

8.11 miltenyi biotec gmbh 233

8.11.1 Overview 233

8.11.2 Financials 233

8.11.3 Products & services 234

8.11.4 Strategy 235

8.11.5 Developments 236

8.12 perkinelmer, inc. 237

8.12.1 Overview 237

8.12.2 Financials 237

8.12.3 Products & services 240

8.12.4 Strategy 243

8.12.5 Developments 245

8.13 promega corporation 248

8.13.1 Overview 248

8.13.2 Financials 248

8.13.3 Products & services 249

8.13.4 Strategy 249

8.13.5 Developments 250

8.14 Scanco medical ag 251

8.14.1 Overview 251

8.14.2 Financials 251

8.14.3 Products & services 251

8.14.4 Strategy 252

8.14.5 Developments 253

8.15 Siemens AG 254

8.15.1 Overview 254

8.15.2 Financials 254

8.15.3 Products & services 258

8.15.4 Strategy 259

8.15.5 Developments 260

8.16 sofie biosciences, inc. 261

8.16.1 Overview 261

8.16.2 Financials 261

8.16.3 Products & services 262

8.16.4 Strategy 262

8.16.5 DEVELOPMENTS 262

8.17 Targeson, inc. 264

8.17.1 Overview 264

8.17.2 Financials 264

8.17.3 Products & services 264

8.17.4 Strategy 265

8.17.5 Developments 266

8.18 uvp, llc. 268

8.18.1 Overview 268

8.18.2 Financials 268

8.18.3 Products & services 268

8.18.4 Strategy 269

8.18.5 Developments 269

List of TableS

TABLE 1 Global pre-clinical imaging (IN VIVO) market revenue,

by segments, 2010 – 2017 ($MILLION) 27

TABLE 2 GLOBAL pre-clinical imaging (in vivo) Systems market revenue, by technology, 2010 – 2017 ($mILLION) 53

TABLE 3 pre-clinical imaging (in vivo) Systems market revenue,

by geography, 2010 – 2017 ($mILLION) 54

TABLE 4 GLOBAL pre-clinical STANDALONE systems market revenue,

by TECHNOLOGY, 2010 – 2017 ($mILLION) 55

TABLE 5 pre-clinical STANDALONE systems market revenue,

by geography, 2010 – 2017 ($mILLION) 57

TABLE 6 GLOBAL pre-clinical standalone Nuclear imaging systems market revenue, by technology, 2010 – 2017 ($mILLION) 58

TABLE 7 pre-clinical standalone Nuclear imaging systems market revenue, by geography, 2010 – 2017 ($mILLION) 59

TABLE 8 pre-clinical Micro-SPECT systems market revenue,

by geography, 2010 – 2017 ($mILLION) 61

TABLE 9 pre-clinical Micro-pet systems market revenue,

by geography, 2010 – 2017 ($mILLION) 62

TABLE 10 GLOBAL pre-clinical optical imaging systems market revenue, by technology, 2010 – 2017 ($mILLION) 64

TABLE 11 pre-clinical optical imaging systems market revenue,

by geography, 2010 – 2017 ($mILLION) 65

TABLE 12 pre-clinical Fluorescence systems market revenue,

by geography, 2010 – 2017 ($mILLION) 66

TABLE 13 pre-clinical Bioluminescence systems market revenue,

by geography, 2010 – 2017 ($mILLION) 67

TABLE 14 pre-clinical Near Infrared Fluorescence systems market revenue, by geography, 2010 – 2017 ($mILLION) 69

TABLE 15 pre-clinical Micro-MRI systems market revenue,

by geography, 2010 – 2017 ($mILLION) 71

TABLE 16 pre-clinical Micro-CT systems market revenue,

by geography, 2010 – 2017 ($mILLION) 73

TABLE 17 pre-clinical Micro-Ultrasound systems market revenue,

by geography, 2010 – 2017 ($mILLION) 75

TABLE 18 pre-clinical Multimodal Nuclear imaging systems market revenue, by geography, 2010 – 2017 ($mILLION) 76

TABLE 19 pre-clinical Multimodal Nuclear imaging systems market revenue, by technology, 2010 – 2017 ($mILLION) 77

TABLE 20 pre-clinical SPECT/CT systems market revenue, by geography, 2010 – 2017 ($mILLION) 78

TABLE 21 pre-clinical SPECT/MRI systems market revenue,

by geography, 2010 – 2017 ($mILLION) 79

TABLE 22 pre-clinical PET/CT systems market revenue,

by geography, 2010 – 2017 ($mILLION) 81

TABLE 23 pre-clinical PET/MRI systems market revenue,

by geography, 2010 – 2017 ($mILLION) 82

TABLE 24 GLOBAL pre-clinical Imaging Agents & Radiotracers systems market revenue, by products, 2010 – 2017 ($mILLION) 85

TABLE 25 pre-clinical Imaging Agents & Radiotracers market revenue, by geography, 2010 – 2017 ($mILLION) 87

TABLE 26 GLOBAL pre-clinical nuclear imaging Radiotracers market revenue, by technology, 2010 – 2017 ($mILLION) 88

TABLE 27 pre-clinical Nuclear Imaging Radiotracers market revenue, by geography, 2010 – 2017 ($mILLION) 88

TABLE 28 GLOBAL pre-clinical PET Radiotracers market revenue,

by radioisotopes, 2010 – 2017 ($mILLION) 90

TABLE 29 pre-clinical PET Radiotracers market revenue, by geography, 2010 – 2017 ($mILLION) 91

TABLE 30 Examples of PET tracers used in animal imaging 92

TABLE 31 pre-clinical Fluorine-18 based Radiotracers market revenue, by geography, 2010 – 2017 ($mILLION) 93

TABLE 32 pre-clinical Carbon-11 based Radiotracers market revenue, by geography, 2010 – 2017 ($mILLION) 94

TABLE 33 pre-clinical Copper-64 based Radiotracers market revenue, by geography, 2010 – 2017 ($mILLION) 95

TABLE 34 pre-clinical Other PET Radiotracers market revenue,

by geography, 2010 – 2017 ($mILLION) 96

TABLE 35 GLOBAL pre-clinical SPECT Probes market revenue,

by radioisotopes, 2010 – 2017 ($mILLION) 97

TABLE 36 pre-clinical SPECT Probes market revenue, by geography, 2010 – 2017 ($mILLION) 98

TABLE 37 pre-clinical Technetium-99m based probes market revenue,

by geography, 2010 – 2017 ($mILLION) 99

TABLE 38 pre-clinical Iodine-131 based probes market revenue,

by geography, 2010 – 2017 ($mILLION) 100

TABLE 39 pre-clinical Gallium-67 based probes market revenue,

by geography, 2010 – 2017 ($mILLION) 101

TABLE 40 pre-clinical Thallium-201 based probes market revenue,

by geography, 2010 – 2017 ($mILLION) 102

TABLE 41 pre-clinical Other SPECT probes market revenue,

by geography, 2010 – 2017 ($mILLION) 103

TABLE 42 GLOBAL pre-clinical Optical Imaging reagents market revenue, by products, 2010 – 2017 ($mILLION) 104

TABLE 43 pre-clinical Optical Imaging reagents market revenue,

by geography, 2010 – 2017 ($mILLION) 105

TABLE 44 GLOBAL pre-clinical Bioluminescent agents market revenue, by products, 2010 – 2017 ($mILLION) 106

TABLE 45 pre-clinical Bioluminescent agents market revenue,

by geography, 2010 – 2017 ($mILLION) 107

TABLE 46 pre-clinical Luciferins Imaging reagents market revenue,

by geography, 2010 – 2017 ($mILLION) 108

TABLE 47 pre-clinical Proluciferins Imaging reagents market revenue, by geography, 2010 – 2017 ($mILLION) 110

TABLE 48 pre-clinical Coelenterazine Imaging reagents market revenue, by geography, 2010 – 2017 ($mILLION) 111

TABLE 49 pre-clinical Other Bioluminescent Imaging reagents market revenue, by geography, 2010 – 2017 ($mILLION) 112

TABLE 50 GLOBAL Fluorescent Imaging reagents market revenue,

by products, 2010 – 2017 ($mILLION) 113

TABLE 51 pre-clinical Fluorescent Imaging reagents market revenue, by geography, 2010 – 2017 ($mILLION) 114

TABLE 52 pre-clinical Green fluorescent proteins Imaging reagents market revenue, by geography, 2010 – 2017 ($mILLION) 115

TABLE 53 pre-clinical Red fluorescent proteins Imaging reagents market revenue, by geography, 2010 – 2017 ($mILLION) 116

TABLE 54 pre-clinical Infrared dyes market revenue, by geography, 2010 – 2017 ($mILLION) 118

TABLE 55 pre-clinical Other Fluorescent Imaging agents market revenue, by geography, 2010 – 2017 ($mILLION) 119

TABLE 56 GLOBAL pre-clinical MRI contrast reagents market revenue, by products, 2010 – 2017 ($mILLION) 120

TABLE 57 pre-clinical MRI contrast reagents market revenue,

by geography, 2010 – 2017 ($mILLION) 121

TABLE 58 pre-clinical Gadolinium-based MRI Imaging agents market revenue, by geography, 2010 – 2017 ($mILLION) 122

TABLE 59 pre-clinical Iron-based MRI Imaging agents market revenue, by geography, 2010 – 2017 ($mILLION) 123

TABLE 60 GLOBAL pre-clinical CT contrast reagents market revenue,

by products, 2010 – 2017 ($mILLION) 124

TABLE 61 pre-clinical CT contrast reagents market revenue,

by geography, 2010 – 2017 ($mILLION) 125

TABLE 62 pre-clinical Iodine-based CT Imaging agents market revenue, by geography, 2010 – 2017 ($mILLION) 126

TABLE 63 pre-clinical Barium-based CT Imaging agents market revenue, by geography, 2010 – 2017 ($mILLION) 127

TABLE 64 pre-clinical Gastrografin-based CT Imaging agents market revenue, by geography, 2010 – 2017 ($mILLION) 128

TABLE 65 pre-clinical Ultrasound contrast reagents market revenue, by geography, 2010 – 2017 ($mILLION) 130

TABLE 66 pre-clinical imaging (in vivo) market revenue, by geography, 2010 – 2017 ($million) 133

TABLE 67 North america: pre-clinical imaging (in vivo) market revenue, by Technology, 2010 – 2017 ($mILLION) 135

TABLE 68 North america: pre-clinical imaging (in vivo) Systems market revenue, by Technology, 2010 – 2017 ($mILLION) 135

TABLE 69 North america: pre-clinical STANDALONE imaging systems market revenue, by technology, 2010 – 2017 ($mILLION) 136

TABLE 70 North america: pre-clinical standalone Nuclear Imaging Systems market revenue, by technology, 2010 – 2017 ($mILLION) 137

TABLE 71 North america: pre-clinical optical imaging systems market revenue, by technology, 2010 – 2017 ($mILLION) 138

TABLE 72 North america: pre-clinical Imaging Agents & Radiotracers market revenue, 2010 – 2017 ($mILLION) 139

TABLE 73 Europe: pre-clinical imaging (in vivo) market revenue,

by Technology, 2010 – 2017 ($mILLION) 141

TABLE 74 Europe: pre-clinical imaging (in vivo) Systems market revenue, by technology, 2010 – 2017 ($mILLION) 141

TABLE 75 Europe: pre-clinical STANDALONE imaging systems market revenue, by technology, 2010 – 2017 ($mILLION) 142

TABLE 76 Europe: pre-clinical standalone Nuclear Imaging Systems market revenue, by technology, 2010 – 2017 ($mILLION) 143

TABLE 77 Europe: pre-clinical optical imaging systems market revenue, by technology, 2010 – 2017 ($mILLION) 143

TABLE 78 Europe: pre-clinical Imaging Agents & Radiotracers market revenue, by technology, 2010 – 2017 ($mILLION) 144

TABLE 79 Asia-Pacific: pre-clinical imaging (in vivo) market revenue, by Technology, 2010 – 2017 ($mILLION) 146

TABLE 80 Asia-Pacific: pre-clinical imaging (in vivo) Systems market revenue, by technology, 2010 – 2017 ($mILLION) 147

TABLE 81 Asia-Pacific: pre-clinical STANDALONE imaging systems market revenue, by technology, 2010 – 2017 ($mILLION) 148

TABLE 82 Asia-Pacific: pre-clinical standalone Nuclear Imaging Systems market revenue, by technology,

2010 – 2017 ($mILLION) 149

TABLE 83 Asia-Pacific: pre-clinical optical imaging systems market revenue, by technology, 2010 – 2017 ($mILLION) 150

TABLE 84 Asia-Pacific: pre-clinical Imaging Agents & Radiotracers market revenue, by technology, 2010 – 2017 ($mILLION) 151

TABLE 85 Row: pre-clinical imaging (in vivo) market revenue,

by technology, 2010 – 2017 ($mILLION) 152

TABLE 86 RoW: pre-clinical imaging (in vivo) Systems market revenue, by technology, 2010 – 2017 ($mILLION) 153

TABLE 87 RoW: pre-clinical STANDALONE imaging systems market revenue, by technology, 2010 – 2017 ($mILLION) 154

TABLE 88 RoW: pre-clinical standalone Nuclear Imaging Systems market revenue, by technology, 2010 – 2017 ($mILLION) 155

TABLE 89 RoW: pre-clinical optical imaging systems market revenue, by technology, 2010 – 2017 ($mILLION) 155

TABLE 90 RoW: pre-clinical Imaging Agents & Radiotracers market revenue, by technology, 2010 – 2017 ($mILLION) 156

TABLE 91 MERGERS & ACQUISITIONS, 2010 –2012 161

TABLE 92 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS &

JOINT VENTURES, 2010 – 2012 163

TABLE 93 NEW PRODUCT LAUNCH, 2009 – 2012 169

TABLE 94 EXPANSION, 2010 – 2012 177

TABLE 95 OTHER DEVELOPMENTS, 2009 –2012 178

TABLE 96 agilent technologies, inc.: Total Revenue and R&D Expenses, 2009 – 2011 ($Million) 180

TABLE 97 agilent technologies, inc.: Total revenue, by segments,

2009 – 2011 ($Million) 180

TABLE 98 agilent technologies, inc.: total revenue, by geography, 2009 – 2011 ($Million) 181

TABLE 99 bruker corporation: Total Revenue And R&D Expenditure, 2009 - 2011 ($Million) 194

TABLE 100 bruker corporation: Total revenue, by segments,

2009 – 2011 ($Million) 195

TABLE 101 bruker corporation: Total revenue, by segments,

2009 – 2011 ($Million) 196

TABLE 102 bruker corporation: total revenue, by Scientific instruments segments, 2009 – 2011 ($Million) 196

TABLE 103 bruker corporation: total revenue, by Geography,

2009 – 2011 ($Million) 197

TABLE 104 fujifilm holdings corporation: Total Revenue and R&D Expenses, 2010 – 2012 ($Million) 205

TABLE 105 fujifilm holdings corporation: Total revenue, by segments, 2010 – 2012 ($Million) 206

TABLE 106 fujifilm holdings corporation: total revenue, by geography, 2010 – 2012 ($Million) 206

TABLE 107 genovis ab: Total Revenue and R&D Expenses,

2009 – 2011 ($Thousand) 213

TABLE 108 genovis ab: total revenue, by geography,

2009 – 2011 ($thousand) 213

TABLE 109 Life Technologies Corporation: Total Revenue and R&D Expenses, 2009 – 2011 ($Million) 225

TABLE 110 life technologies corporation: Total revenue, by segments, 2009 – 2011 ($Million) 225

TABLE 111 life technologies corporation: total revenue,

by geography, 2009 – 2011 ($Million) 226

TABLE 112 perkinelmer inc: Total Revenue and R&D Expenses,

2009 – 2011 ($Million) 238

TABLE 113 perkinelmer inc: Total revenue, by segments,

2009 – 2011 ($Million) 238

TABLE 114 perkinelmer, inc: total revenue, by geography,

2009 – 2011 ($Million) 239

TABLE 115 siemens AG: Total Revenue and R&D Expenses,

2009 – 2011 ($Million) 255

TABLE 116 siemens AG: Total revenue, by segments,

2009 – 2011 ($Million) 256

TABLE 117 siemens ag: total revenue, by geography,

2009 – 2011 ($Million) 257

List of FIGURES

FIGURE 1 Global pre-clinical imaging (in vivo) systems market,

by technology, 2012 Vs 2017 28

FIGURE 2 Global pre-clinical imaging (in vivo) reagents market,

by technology, 2012 Vs 2017 29

FIGURE 3 pre-clinical imaging (in vivo) market, by geography, 2012 30

FIGURE 4 pre-clinical imaging (in vivo) technologies market segmentation 34

FIGURE 5 pre-clinical imaging (in vivo) market segmentation 35

FIGURE 6 pre-clinical imaging (in vivo) systems market segmentation 37

FIGURE 7 Comparative chart on pre-clinical imaging (in vivo) modalities 38

FIGURE 8 pre-clinical imaging (in vivo) reagents market segmentation 39

FIGURE 9 Market dynamics 40

FIGURE 10 Global pre-clinical imaging market share,

by technology, 2012 48

FIGURE 11 Global pre-clinical imaging market share,

by key players, 2012 49

FIGURE 12 Global pre-clinical nuclear imaging market share,

by key players, 2012 50

FIGURE 13 Global pre-clinical optical imaging market share,

by key players, 2012 50

FIGURE 14 pre-clinical imaging systems & reagents market share,

by geography, 2012 vs. 2017 51

FIGURE 15 GLOBAL pre-clinical STANDALONE systems market revenue,

by TECHNOLOGY, 2012 Vs 2017 ($mILLION) 56

FIGURE 16 GLOBAL pre-clinical Imaging reAgents & Radiotracers systems market revenue, by products, 2010 – 2017 ($mILLION) 86

FIGURE 17 Global Pre-clinical imaging (In vivo) market Share,

By growth strategies, 2010 – 2012 157

FIGURE 18 Key players focusing on new product launch strategy,

2010 – 2012 158

FIGURE 19 Key players focusing on partnerships & collaborations strategy, 2010 – 2012 159

FIGURE 20 Key players focusing on Mergers & acquisitions strategy, 2010 – 2012 160

To order this report:

Medical_Imaging Industry: Pre-Clinical Imaging (In vivo) Market – By Systems and Reagents [Micro-PET, Optical Imaging, Micro-MRI, Micro-SPECT, Micro-Ultrasound, Micro-CT & Multimodality/Hybrid Imaging Modalities] - Competitive Analysis & Global Forecasts to 2017

Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.